MarketCap
Facebook
X
Telegram
Hutchison China MediTech Limited Financial Ratios 2025-2011 | HCM
Brief overview of Hutchison China MediTech Limited's financial ratios
Ratios are assessed across five available annual reports in the 2021–2025 interval.
Key multiples at the end of the period are P/E 26.26x (median 127.39x), P/S 21.88x (median 21.88x), P/B 9.59x (median 17.27x). The combined multiple level is about 44.5% below the company's historical norm, suggesting more cautious expectations.
Earnings yield calculated as 1/P/E is about 3.8%, showing current profit per unit of share price.
Capital efficiency is characterized by ROE 36.9%, ROA 26.1%, ROCE -3.2%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
Current PEG of 12.68x points to a premium over forecast earnings momentum.
A longer cycle, from -10.5 days to 95.8 days, indicates slower release of cash from operations.
Conclusion
Hutchison China MediTech Limited's valuation is lower, but weak quality metrics call for caution. Recovery in earnings and capital returns is the key catalyst.
Annual Financial Ratios Hutchison China MediTech Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
26.3 | 339.8 | 127.4 | -31.2 | -111.0 | -159.5 | -146.4 | -231.7 | -776.9 | -19.6 | - | - | - | - | - |
P/S |
21.9 | 20.3 | 15.3 | 26.4 | 60.7 | 88.0 | 75.8 | 80.9 | 86.1 | 3.9 | - | - | - | - | - |
EPS |
0.5 | 0.0 | 0.1 | -0.4 | -0.2 | -0.2 | -0.2 | -0.1 | -0.0 | 0.2 | -0.6 | -0.6 | - | - | - |
EV (Enterprise Value) |
12.4 B | 13.2 B | 13.1 B | 11.3 B | 21.9 B | 20 B | 15.6 B | 17.4 B | 20.8 B | 902 M | 95.5 M | 60.1 M | 80.8 M | 126 M | 117 M |
EBITDA per Share |
-0.03 | -0.04 | 0.03 | -0.47 | -0.41 | -0.27 | -0.21 | -0.13 | -0.08 | -0.782 | - | - | - | - | - |
EV/EBITDA |
-480.8 | -419.9 | 492.5 | -28.4 | -66.6 | -110.3 | -115.5 | -16.3 | -43.5 | -17.4 | - | - | - | - | - |
PEG |
-0.44 | -6.95 | 12.68 | -0.71 | -4.84 | 1.32 | 1.19 | -2.37 | -13.59 | 0.0 | - | - | - | - | - |
P/B |
9.6 | 16.6 | 17.3 | 17.7 | 20.8 | 38.7 | 49.6 | 42.0 | 181.8 | 4.1 | - | - | - | - | - |
P/CF |
-185.6 | 25798.2 | 58.6 | -41.9 | -105.8 | -323.2 | -191.9 | -527.6 | -2322.6 | -748.8 | - | - | - | - | - |
ROE % |
36.91 | 4.96 | 13.80 | -59.12 | -18.72 | -24.23 | -33.88 | -18.15 | -5.53 | -21.08 | - | - | - | - | - |
ROA % |
26.06 | 2.96 | 7.87 | -35.05 | -14.18 | -17.36 | -22.79 | -14.06 | -12.81 | -12.56 | - | - | - | - | - |
ROCE % |
-3.16 | -5.75 | 2.52 | -66.79 | -31.58 | -34.76 | -42.35 | -21.06 | -11.01 | -18.88 | - | - | - | - | - |
Current Ratio |
3.5 | 2.5 | 2.4 | 2.6 | 4.1 | 3.5 | 3.1 | 4.4 | 2.2 | 1.8 | - | - | - | - | - |
DSO |
93.9 | 78.9 | 46.8 | 41.9 | 23.9 | 70.5 | 72.7 | 67.0 | 59.9 | 68.9 | - | - | - | - | - |
DIO |
49.7 | 52.7 | 50.8 | 54.2 | 110.6 | 103.3 | 112.5 | 124.4 | 180.8 | - | - | - | - | - | - |
DPO |
47.8 | 41.2 | 51.0 | 65.9 | 145.0 | 159.6 | 195.7 | 258.2 | 402.1 | - | - | - | - | - | - |
Operating Cycle |
143.6 | 131.6 | 97.6 | 96.2 | 134.5 | 173.8 | 185.2 | 191.4 | 240.7 | - | - | - | - | - | - |
Cash Conversion Cycle |
95.8 | 90.3 | 46.6 | 30.3 | -10.5 | 14.2 | -10.5 | -66.7 | -161.4 | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Hutchison China MediTech Limited
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.53 | 0.53 | 0.04 | 0.03 | 0.12 | 0.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.03 | - | - | - | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.03 | - | -0.04 | -0.02 | 0.03 | 0.14 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.05 | - | - | - | -0.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
82.38 | 59.26 | 43.80 | 33.54 | 27.60 | 21.55 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.29 | - | - | - | -2.45 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
56.69 | 38.50 | 25.87 | 19.22 | 7.87 | 12.99 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.69 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-12.92 | -7.24 | 7.32 | 3.48 | 1.97 | 14.28 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.59 | - | - | - | -5.23 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.5 | 3.3 | 2.5 | 2.5 | 2.4 | 2.6 | - | - | - | - | 4.1 | - | 4.9 | - | 3.5 | - | 3.3 | - | 3.1 | 3.9 | 4.0 | 3.9 | 4.4 | - | 4.8 | - | 5.3 | - | 2.6 | - | 2.5 | - | - | - | 1.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
22.8 | 49.7 | 22.6 | 40.9 | 13.4 | 11.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.1 | - | - | - | 33.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
12.2 | 26.9 | 12.7 | 119.7 | 12.4 | 54.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 120.9 | - | - | - | 68.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
12.1 | 23.5 | 11.2 | 98.7 | 10.8 | 54.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 227.8 | - | - | - | 141.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 193.0 | - | - | - | 102.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.8 | - | - | - | -39.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Hutchison China MediTech Limited, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Russia
USA
Canada
Germany
China
Israel
France
Britain
Belgium
